BIOA

Conviction 32HealthcareScan · Thu, Sep 24, 2026

BioAge Labs, Inc. (BIOA) closed at $7.25 (-8.11%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 28, RS Rating 94, -71.1% from its 52-week high, -43.5% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

BIOA$7.25-8.11%

ResistanceSupportVol 14

Vol MA14 759.2K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

BioAge Labs, Inc.PHARMACEUTICAL PREPARATIONSwww.bioagelabs.com ↗

Price7.25

Change-8.11%

Gap-0.38%

Rel volume2.16×

Avg volume707.15K

Avg $ vol6.05M

SMA 208.78

SMA 5012.39

SMA 20016.87

Price vs 50-41.50%

Price vs 200-57.02%

MA stackbearish

50/200 cross—

Supertrenddown · 9.32

RSI (14)28

MACD hist0.15

MACD cross—

Stoch %K / %D2 / 16

ADX (14)42

+DI / −DI13 / 37

RSI divergence—

MACD divergence—

ATR %9.37%

ADR %5.86%

52w high25.10

52w low5.11

From 52w high-71.12%

Above 52w low+41.88%

New 52w highNo

SqueezeOff

Bollinger width35.94%

%B0.02

Donchian pos1.64%

Donchian high10.25

Donchian low7.20

AVWAP (52w high)12.46

vs AVWAP high-41.80%

AVWAP (52w low)15.06

vs AVWAP low-51.85%

OBV trendDown

Chaikin MF (20)-0.10

Today vs 20d2.16×

Avg vol (14d)759.2K

Avg vol (20d)707.15K

Avg $ vol (20d)6.05M

Market cap332.75M

RS Rating94 / 99

RS 3m (vs SPY)-72.44%

RS 6m (vs SPY)-72.64%

RS line new highNo

Trend template3/8

Technical rank4.8

1 week-10.38%

1 month-28.29%

3 months-67.95%

6 months-55.82%

1 year+46.76%

YTD-43.49%

P/E-4.13

P/B0.89

P/S36.99

P/FCF-4.04

EPS-2.24

Div yield—

ROE-21.50%

ROA-20.31%

Debt/Eq0.00

Current17.19

EV/EBITDA—

Gross margin—

Net margin-896.11%

Rev growth—

EPS growth-13.35%

Price target35.63

Target upside391.45%

Analyst ratingBuy

Institutional90.04%

Ent. value258.79M

Revenue2.45M

Net income-26.1M

Gross profit—

Free cash flow-82.35M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out44.45M

Employees62

ListedThu, Sep 26, 2024

Free float18.5M

Float %51.6%

Short interest2.72M

Days to cover4.7d

Short volume32.0%

Squeeze score68 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.58 vs −$0.65

Last surprise+10.8% beat

Setup gradeD

Conviction32 / 100

Pattern quality—

Tech rank4.8 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance11.41

Support8.39

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BIOA

All disclosures →

No recent disclosed trades by Congress in BIOA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BIOA

Insider	Side	Shares	Value	Traded	Filed
GOLDSTEIN DOV A MD Chief Financial Officer · Common Stock · 2026-04-23	Exercise	3.54K	$16K	2026-04-23	2026-04-24
GOLDSTEIN DOV A MD Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-23	Exercise	3.54K	$0	2026-04-23	2026-04-24

SEC filings

EDGAR filings in BIOA · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.